Helius Medical Technologies Inc launches its Patient Therapy Access Program (PTAP), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (PoNS) Therapy at a significantly reduced price. PoNS is indicated in the US for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from multiple sclerosis (MS) and is available by prescription only.

“In April, we announced that the first patients in the United States had purchased the PoNS device on a cash pay basis and begun treatment. We are also offering an opportunity for MS patients to be treated with PoNS Therapy through our previously announced Therapeutic Experience Program (TEP), gathering important clinical evidence in a real-world environment while we pursue reimbursement from third-party payers and CMS. Our goal is to bring treatment to as many qualifying patients as possible and we are proud to introduce our Patient Therapy Access Program for potential first-time users,” stated Dane Andreeff, President and Chief Executive Officer of Helius.

“With the proper prescription and a letter of medical necessity, people struggling with MS in the U.S. will be able to access PoNS Therapy at a greatly reduced price. We believe this program will accelerate the adoption of PoNS Therapy and help to establish PoNS as the standard of care for MS patients with gait deficit. PTAP participants will also be invited to join Helius’s upcoming registry program, which is designed to collect important health economic information to establish the value of PoNS on key therapeutic outcomes and will complement the data gleaned through TEP,” concluded Mr. Andreeff.

The Patient Therapy Access Program is currently available and expected to run through December 31, 2022.

[Source(s): Helius Medical Technologies Inc, GlobeNewswire]